BioAge Labs, Inc.

Contributing Author

Recent Articles by BioAge Labs, Inc.

Jun-03	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates BIOA GlobeNewswire
May-29	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic BIOA GlobeNewswire
May-27	BioAge Labs to Present at Upcoming Investor Conferences BIOA GlobeNewswire
May-06	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates BIOA GlobeNewswire